News · Longevity & Aging
A blood marker of long-term inflammation went with 43% higher heart risk, in UK Biobank data
Chronic inflammation is blamed for much of heart disease without being measured. Using one blood marker, heart scans and genetics, researchers traced how it tracks with a smaller, faster-beating heart.
- An observational analysis of UK Biobank participants with blood profiling, heart MRI scans and follow-up records.
- Inflammation was measured by GlycA, a blood marker that reflects long-term rather than short-lived inflammation.
- People in the highest fifth for GlycA had 43% higher risk of heart attack, stroke or cardiovascular death.
- Higher GlycA went with smaller heart chamber volumes, less blood pumped per beat and a faster resting heart rate.
- Trunk fat, smoking, psychological distress and low income were the strongest drivers of the marker.
Inflammation is the word doctors reach for to explain why stress, smoking, belly fat and poverty end up as heart disease. Outside research, it is rarely measured. That makes the story hard to check.
A study in the European Journal of Preventive Cardiology used one blood marker of long-running inflammation, heart scans and genetic scores across hundreds of thousands of UK Biobank participants. Higher inflammation went with a smaller, faster-beating heart and, years later, more heart attacks and strokes.
What chronic inflammation means for the heart
MedlinePlus defines the territory plainly: heart disease is a term that includes several types of heart conditions, with coronary artery disease the most common, and it notes that heart disease is the leading cause of death in the United States.
Inflammation enters that story as a slow burn. The authors set out the gap: chronic inflammation is a major driver of cardiovascular diseases, but mechanisms linking systemic inflammation to cardiac remodelling remain incompletely understood.
How the inflammation and heart study worked
The researchers drew on subsets of 488 079 UK Biobank participants who had blood profiling, heart scans, or both, plus years of follow-up records. Inflammation was quantified using glycoprotein acetyls (GlycA), a blood signal that reflects several inflammation-related proteins at once and stays steadier over time than the inflammation tests used in clinics.
Heart structure came from magnetic resonance scans, read by machine learning. The team then tested which of 80 inflammatory proteins might sit on the path between inflammation and the heart. They also asked which exposures predicted higher GlycA, and how genetic risk scores changed the picture.
What higher inflammation looked like on the scans
The hearts of people with more inflammation were subtly different. Higher GlycA went with a smaller left ventricle at the end of filling and less blood pumped per beat, with compensatory increased heart rate making up the shortfall.
The risk followed. The highest fifth for GlycA had 43% higher risk versus the lowest of a heart attack, a stroke or death from heart or blood vessel disease. One protein stood out on the path between the two: interleukin-1 receptor antagonist statistically mediated 27% of the association with chamber size, pointing at the interleukin-1 pathway that anti-inflammatory heart drugs already target.
Why the drivers of inflammation matter
The study also asked what pushes the marker up. Trunk fat, smoking, psychological distress and low income were the strongest drivers. That puts body shape, tobacco, stress and money on the same footing as biological risk factors.
Genetics shaded those effects. Cardiovascular polygenic risk scores modified associations between environmental exposures, inflammation and heart events, which the authors read as risk reflecting the convergence of inherited and acquired factors. In plain terms: the same stressful, smoky, sedentary life may cost some people more than others.
What an observational inflammation study cannot prove
GlycA is a marker, not a mechanism, and people with higher levels differ in many ways that no adjustment fully captures. The mediation analysis is statistical: it identifies proteins that fit the pathway, not proteins proven to do the work.
The heart scans were taken once, so this compares people rather than tracking change. UK Biobank volunteers are healthier and better off than most, and largely of European descent, so the genetic findings may not travel. And a 43% difference sits on a low baseline risk for most middle-aged people.
What this changes about lowering inflammation
There is no prescription here. Anti-inflammatory drugs for the heart exist, but they are reserved for specific patients, and nothing in this study tells anyone to seek one.
What it does is give a measurable thread connecting familiar exposures to the heart. The practical levers remain smoking, abdominal weight, activity, sleep and the treatment of conditions that keep inflammation running, along with the harder, structural business of stress and income.
People also ask
What did the study find?
Higher GlycA was associated with reduced left ventricular (main pumping chamber) indexed end-diastolic volume and stroke volume, with a compensatory higher heart rate. Interleukin-1 receptor antagonist statistically mediated 27% of the effect on end-diastolic volume. The highest GlycA quintile had 43% higher risk of major adverse cardiovascular events than the lowest (adjusted hazard ratio 1.43, 95% CI 1.38 to 1.49).
What is GlycA?
Glycoprotein acetyls: a signal measured by nuclear magnetic resonance spectroscopy in blood that reflects several inflammation-related proteins at once. It is steadier over time than C-reactive protein, so it captures long-running inflammation rather than a passing infection.
What does a smaller heart chamber mean here?
The left ventricle was filling with less blood before each beat and pushing out less per beat, with a faster heart rate making up the difference. It is a subtle pattern seen on scans, not heart failure.
What raised inflammation the most?
Trunk fat mass, current smoking, psychological distress and low socioeconomic status were the strongest determinants of GlycA in this analysis.
Do genes matter?
Genetic risk scores changed how strongly environmental exposures tracked with inflammation and with heart events, which the authors read as inherited and acquired risk converging.
Can I get my inflammation measured?
GlycA is mostly a research measure. Clinically, the levers that lower inflammation are the familiar ones: not smoking, moving more, losing excess abdominal weight, sleeping, and treating conditions that keep inflammation up. This is general information rather than medical advice.